IQVIA
↗Durham, North Carolina, United States (Primary) / Danbury, Connecticut, United States (Secondary)
IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company was formed in 2016 through the merger of Quintiles Transnational Corporation and IMS Health, two industry-leading organizations with complementary capabilities. IQVIA leverages an extensive data platform providing access to 1.2 billion non-identified patient records globally, combined with advanced analytics, AI-powered technologies, and deep scientific expertise to accelerate the development and commercialization of innovative medical treatments. Operating across more than 100 countries, IQVIA serves as an integrated information and technology-enabled healthcare service provider that connects people, processes, and technology across the entire pharmaceutical value chain from research and development through commercialization.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Contract Research Organization (CRO)
Sub-Industry:Clinical research, healthcare data analytics, real-world evidence
SIZE & FINANCIALS
Employees:10000+
Revenue:$15.41B (2024)
Founded:1982
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:IQV
Market Cap:$38.39B
PIPELINE
Stage:N/A - Service Provider
Lead Drug Stage:N/A - IQVIA is a CRO, not a drug developer
Modalities:Clinical trial management, Real-world evidence, Healthcare data analytics, Regulatory affairs, Pharmacovigilance
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Quintiles (merged into IQVIA), IMS Health (merged into IQVIA)
Key Partnerships:Amazon Web Services (AWS): Preferred Agentic Cloud Provider for AI-powered platform, NVIDIA: Collaboration to combine IQVIA Connected Intelligence with NVIDIA AI Foundry service, Veeva Systems: Long-term clinical and commercial partnerships; resolution of legal disputes (August 2025), Flagship Pioneering: Strategic collaboration to accelerate biotech innovation through AI-powered drug development
COMPETITION
Position:Leader
Competitors:ICON plc, Thermo Fisher Scientific (PPD), Charles River Laboratories, Syneos Health, PAREXEL, WuXi AppTec, Pharmaron Beijing, Medpace +2 more
LEADERSHIP
Key Executives:
Ari Bousbib - Chairman and Chief Executive Officer (CEO)
Ron Bruehlman - Executive Vice President and Chief Financial Officer (CFO)
Jeffrey Spaeder - Chief Medical and Scientific Officer
Trudy Stein - Executive Vice President and Chief Human Resources Officer
Eric Sherbet - Executive Vice President and General Counsel
Scientific Founders:Dennis B. Gillings (Quintiles founder, 1982), Gary Koch (Quintiles founder, 1982)
Board Members:Ari Bousbib (Chairman and CEO), Colleen A. Goggins (Director, Chair of Nominating and Governance Committee), Dr. William G. Kaelin Jr. (Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with IQVIA. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.